So, for nonmanifesting or asymptomatic carriers of DMD, the proportion of the preferential inactivation (usually nearing 50% to 80%) could also vary even among different subjects harboring the same variant of DMD [29], even excluding any clinical, electrophysiological, or pathological evidence of neuromuscular diseases. This evidence concerns the gene DMD and neuromuscular disease.